Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in Relapsed ALK Positive Lymphoma
NCT03505554Phase 2Completed
- Sponsor
- University of Milano-Bicocca
- Start
- Sep 2019
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in anaplastic large cell lymphoma (ALCL), sponsored by University of Milano-Bicocca. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2019; status: completed.
02
Drugs
lorlatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03505554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505554.